Cargando…
Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study
BACKGROUND: The management of severe asthma-associated symptoms is essential since they are distressing to the affected patients, and also greatly impair their quality of life. Dupilumab, a monoclonal antibody, blocks interleukin (IL)-4 and IL-13 signaling, both of which are crucial in acquired and...
Autores principales: | Tani, Nozomi, Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Sato, Izumi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993019/ https://www.ncbi.nlm.nih.gov/pubmed/33815789 http://dx.doi.org/10.4081/mrm.2021.736 |
Ejemplares similares
-
Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020) -
Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
por: Sato, Izumi, et al.
Publicado: (2020) -
Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer
por: Ogura, Yuri, et al.
Publicado: (2020) -
IgG4‐related lung disease progressing to respiratory failure
por: Kunimatsu, Yusuke, et al.
Publicado: (2020) -
Drug‐induced interstitial lung disease associated with dasatinib coinciding with active tuberculosis
por: Tani, Nozomi, et al.
Publicado: (2020)